A Review of Thrombopoietin Receptor Agonists and Subsequent Development of Thrombosis: Exploring a Hematologic Paradox.

Authors

Gillian Graifman, Ranya Parekh, Rajesh Varma C P, Arun Nair

Published in

Cureus. Volume 18. Issue 9. Pages e115715. Epub Sep 03, 2026.

Abstract

Thrombopoietin receptor agonists (TPO-RAs) are drugs that increase platelet production and reduce bleeding risk. Agents such as romiplostim, eltrombopag, avatrombopag, and lusutrombopag act in different ways to stimulate megakaryopoiesis. These agents are used in both adult and pediatric populations, primarily in chronic immune thrombocytopenia, severe aplastic anemia, and myelodysplastic syndrome, as well as pre-procedural in patients with chronic liver disease. This literature review summarizes the current TPO-RAs and aims to evaluate the risk of thrombus formation. Past studies have been inconsistent in significantly associating thrombotic events with higher platelet counts, medication doses, or drug mechanisms of action. The pathophysiology appears to be multifactorial, with some theories suggesting risk from increased thrombopoiesis with potential alterations in platelet activity or an already prothrombotic patient state due to underlying disease or individual predisposing factors. Risks such as prior thrombus formation, older age, history of splenectomy, antiphospholipid syndrome, prolonged TPO-RA exposure, and thrombotic risk associated with the underlying disease being treated are important to consider not only during treatment initiation but also during continued risk assessment.

PMID:
42829584
Bibliographic data and abstract were imported from PubMed on 04 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.